The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.
Bayer agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses.
Bayer hopes to release its new knockdown herbicide, icafolin-methyl, in Australia in 2028, subject to APVMA approvals and ...
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in ...
Sunderland captain Granit Xhaka has hailed Cole Palmer as “amazing” ahead of the two teams meeting at Stamford Bridge later ...
TipRanks on MSN
Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals, in ...
Esteemed Kompany on MSN
A City youngster is yet to make an impression at Bayer Leverkusen
Claudio Echeverri left Manchester City to spend the 25/26 season out on loan at Bayer Leverkusen. Echeverri is a player who ...
Liverpool could be faced with a defensive emergency against Manchester United after Ibrahima Konate was forced to withdraw ...
The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and ...
Reports vary on how close Steven Gerrard is to being appointed Rangers boss, while Besiktas are reportedly interested in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback